HAE · NYSE
Haemonetics (HAE) Stock Price & Fundamentals
Haemonetics (HAE) closed at $176.17 on Oct 9, 2026, down 0.09% from the previous close of $176.32.
Share price, past year
1Y −25.72%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $176.17 |
| Sep 30, 2026 | $184.23 |
| Aug 31, 2026 | $192.43 |
| Jul 31, 2026 | $194.22 |
| Jun 30, 2026 | $210.88 |
| May 29, 2026 | $224.87 |
| Apr 30, 2026 | $229.96 |
| Mar 31, 2026 | $232.25 |
| Feb 27, 2026 | $248.71 |
| Jan 30, 2026 | $248.01 |
| Dec 31, 2025 | $234.29 |
| Nov 28, 2025 | $230.85 |
| Oct 31, 2025 | $231.95 |
Key statistics
- Market cap
- $8.01B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $1.35B
- Net income (TTM)
- $96.29M
- Shares outstanding
- 45.5M
- Dividend yield
- —
- 52-week range
- $176.15 – $253.12
Haemonetics's market cap is $8.01B, based on a share price of $176.17 and 45.5M shares outstanding as of Jun 27, 2026.
Financials
Haemonetics reported revenue of $1.33B for fiscal 2026, down 1.97% from fiscal 2025.
Haemonetics earned net income of $97.31M in fiscal 2026, a net margin of 7.3%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2026ended Mar 28, 2026 | $1.33B | −2.0% | $97.31M | 7.3% | $2.05 | $260.44M |
| FY2025ended Mar 29, 2025 | $1.36B | +4.0% | $167.68M | 12.3% | $3.31 | $142.45M |
| FY2024ended Mar 30, 2024 | $1.31B | +12.0% | $117.56M | 9.0% | $2.29 | $143.63M |
| FY2023ended Apr 1, 2023 | $1.17B | +17.7% | $115.40M | 9.9% | $2.24 | $81.73M |
| FY2022ended Apr 2, 2022 | $993.20M | +14.1% | $43.38M | 4.4% | $0.84 | $75.75M |
| FY2021ended Apr 3, 2021 | $870.46M | −11.9% | $79.47M | 9.1% | $1.55 | $71.77M |
| FY2020ended Mar 28, 2020 | $988.48M | +2.2% | $76.53M | 7.7% | $1.48 | $109.46M |
| FY2019ended Mar 30, 2019 | $967.58M | +7.0% | $55.02M | 5.7% | $1.04 | $40.32M |
| FY2018ended Mar 31, 2018 | $903.92M | +2.0% | $45.57M | 5.0% | $0.85 | $145.55M |
| FY2017ended Apr 1, 2017 | $886.12M | — | −$26.27M | −3.0% | −$0.51 | $83.60M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2027ended Jun 27, 2026 | $339.38M | $33.01M | $0.72 |
| Q4 FY2026ended Mar 28, 2026 | $346.35M | −$20.15M | — |
| Q3 FY2026ended Dec 27, 2025 | $338.97M | $44.74M | $0.95 |
| Q2 FY2026ended Sep 27, 2025 | $327.32M | $38.68M | $0.81 |
| Q1 FY2026ended Jun 28, 2025 | $321.39M | $34.03M | $0.70 |
| Q4 FY2025ended Mar 29, 2025 | $330.60M | $57.98M | — |
| Q3 FY2025ended Dec 28, 2024 | $348.54M | $37.49M | $0.74 |
| Q2 FY2025ended Sep 28, 2024 | $345.51M | $33.83M | $0.66 |
Company profile
- Name
- Haemonetics Corporation
- Ticker
- HAE
- Exchange
- NYSE
- Industry (SEC SIC)
- Surgical & Medical Instruments & Apparatus
- Headquarters
- 125 Summer Street, Boston, MA 02110
- Incorporated in
- MA
- Fiscal year ends
- April
- SEC CIK
- 0000313143
Recent SEC filings
- Oct 8, 2026
- Aug 18, 2026
- Aug 6, 2026
- Aug 6, 2026
- Jul 28, 2026
- Jun 5, 2026
- May 20, 2026
- May 7, 2026
Frequently asked questions
What is Haemonetics's stock price?
Haemonetics (HAE) closed at $176.17 on Oct 9, 2026, down 0.09% from the previous close of $176.32.
What is Haemonetics's market cap?
Haemonetics's market cap is $8.01B, based on a share price of $176.17 and 45.5M shares outstanding as of Jun 27, 2026.
How much revenue does Haemonetics make?
Haemonetics reported revenue of $1.33B for fiscal 2026, down 1.97% from fiscal 2025.
Does Haemonetics pay a dividend?
Haemonetics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Haemonetics Corporation's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures